2. Academic Validation
  3. Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis

Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis

  • J Med Chem. 2006 Jul 27;49(15):4447-50. doi: 10.1021/jm0603724.
Stephen J Baker 1,  Yong-Kang Zhang,  Tsutomu Akama,  Agnes Lau,  Huchen Zhou,  Vincent Hernandez,  Weimin Mao,  M R K Alley,  Virginia Sanders,  Jacob J Plattner
Affiliations

Affiliation

  • 1 Anacor Pharmaceuticals Inc., 1060 East Meadow Circle, Palo Alto, California 94303, USA. sbaker@anacor.com
PMID: 16854048 DOI: 10.1021/jm0603724
Abstract

A structure-activity relationship investigation for a more efficacious therapy to treat onychomycosis, a fungal Infection of the toe and fingernails, led to the discovery of a boron-containing small molecule, 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690), which is currently in clinical trials for onychomycosis topical treatment.

Figures
Products